Skip to main content
. Author manuscript; available in PMC: 2017 Jul 1.
Published in final edited form as: J Allergy Clin Immunol. 2016 Mar 2;138(1):187–199. doi: 10.1016/j.jaci.2015.11.024

Figure 2. C188–9 decreases histamine or PAF-induced vascular leakage.

Figure 2

Hematocrit values at baseline and after passive systemic anaphylaxis (PSA) induced by (A) histamine or (B) PAF in C188–9 (n=5/group) and vehicle treated mice (n=6/group). (C–D) Evan’s blue leakage in response to IgE/Ag-challenge (C; n=10/group) or compound 48/80 (D; n=5/group) in C188–9 and vehicle treated mice. (E–F) In vitro permeability assay of mouse lung endothelial cells exposed to histamine (E; 1 µM) or PAF (F; 10ug) following pretreatment with DMSO or C188–9 (1 µM; n=3/group). (UT: untreated; His: histamine; PAF: platelet activating factor). Data are representative of 3 independent experiments. Data are expressed as the mean ± S.E.M. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.